News

Ergomed Plc has reported positive results from a Phase 2 study of its insomnia drug Lorediplon, a non-benzodiazepine hypnotic drug that modulates the GABAa receptor.

Genmab A/S has upgraded its guidance for revenue and operating income in 2016 in light of higher than expected royalties on sales of Darzalex (daratumumab), a treatment for multiple myeloma, as well as milestone payments from its licensee Janssen Biotech Inc.

Novo Nordisk A/S has made further adjustments to its financial forecast amidst downward pressure on insulin prices in the US and a decline in market share for its glucagon-like peptide-1 (GLP-1) medicine Victoza.

Biotec Pharmacon ASA, which uses Artic Ocean marine and plant life to develop sophisticated medicinal treatments and analytics, reported increases in revenue for the 2016 fourth quarter and full-year but also saw a widening of its loss.

AstraZeneca Plc says that 2017 should be a turning point for the company as the loss of revenue from legacy products is overtaken by new drug launches, and core research and development spending levels out.

The Roche group was able to grow net income faster than sales in 2016 on the back of a series of new pharmaceutical product launches that included Tecentriq (atezolizumab), its first cancer immunotherapy. Tecentriq is a PD-L1 inhibitor for both bladder and lung cancer.

The US law firm, Hagens Berman Sobol Shapiro LLP, has filed a class action suit against Sanofi SA, Novo Nordisk A/S and Eli Lilly and Company alleging that they have used increasingly wider discounts from the list price of their analogue insulins to gain favour with pharmacy benefit managers and health insurers and thereby gained market share.

Novo Nordisk A/S has turned to the University of Oxford for support in developing new approaches to treat Type 2 diabetes, a disease that affects nearly 9% of the global population. While Novo has a dominant global market position in the field, it is seeking to discover new treatments for people living with the disease and its complications.

Heptares Therapeutics has launched a research partnership with the University of Cambridge to use its discovery platform targeting G protein-coupled receptors (GPCRs) to identify new drugs for cardiovascular disease.

Early clinical data for a therapeutic protein developed by Ablnyx NV to treat patients with psoriasis has demonstrated that the treatment is safe, with some evidence of a reduction in disease activity. The treatment targets the interleukin-17 (IL-17) pathway.